Ajithkumar Sukumaran Selected Research

NUC-1031

1/2021	A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer.
10/2018	Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ajithkumar Sukumaran Research Topics

Disease

2	Neoplasms (Cancer) 03/2021 - 10/2018
2	Biliary Tract Neoplasms (Biliary Tract Cancer) 06/2016 - 02/2016
1	Hepatocellular Carcinoma (Hepatoma) 03/2021
1	Ovarian Neoplasms (Ovarian Cancer) 01/2021
1	Fatigue 10/2018
1	Exanthema (Rash) 02/2016
1	Chest Pain (Chest Pains) 02/2016
1	Disease Progression 02/2016

Drug/Important Bio-Agent (IBA)

3	Gemcitabine FDA Link 10/2018 - 02/2016
2	NUC-1031IBA 01/2021 - 10/2018
2	AZD 6244IBA 06/2016 - 02/2016
2	Cisplatin (Platino)FDA LinkGeneric 06/2016 - 02/2016
1	NivolumabIBA 03/2021
1	IpilimumabIBA 03/2021
1	PlatinumIBA 01/2021
1	Carboplatin (JM8)FDA LinkGeneric 01/2021
1	phosphoramidic acidIBA 10/2018
1	ProTidesIBA 10/2018

Therapy/Procedure

1	Therapeutics 03/2021
1	Drug Therapy (Chemotherapy) 01/2021